Oncolytic viruses and their application to cancer immunotherapy
about
Oncolytic viruses as immunotherapy: progress and remaining challengesPancreatic cancer from bench to bedside: molecular pathways and treatment optionsMechanism of Action and Applications of Interleukin 24 in ImmunotherapyCancer immunotherapy: the beginning of the end of cancer?Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeOncolytic viruses: finally deliveringViro-immune therapy: A new strategy for treatment of pancreatic cancerViruses as nanomedicine for cancerModular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8(+) T-cell Activation Against Tumors.Surgical immune interventions for solid malignancies.Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyInactivated Tianjin strain, a novel genotype of Sendai virus, induces apoptosis in HeLa, NCI-H446 and Hep3B cells.MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer.Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune ResponseEXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMAAssessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus ImmunotherapyCXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trialCurative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.Arming oncolytic viruses to leverage antitumor immunity.Role of NK cells in immunotherapy and virotherapy of solid tumors.Cancer Immunotherapies: Are They as Effective in the Elderly?Metal-dependent Deacetylases: Cancer and Epigenetic RegulatorsPotential and clinical translation of oncolytic measles viruses.Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes VirusesΔPK oncolytic activity includes modulation of the tumour cell milieu.Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.The oncolytic virus ΔPK has multimodal anti-tumor activity.Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaOncolytic herpes simplex virus interactions with the host immune system.Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.Introduction to RNA Vaccines.
P2860
Q26745942-6D06D649-B740-44BF-9F50-0B8431AEB316Q26747524-3A4C93FC-3088-4DE5-AC3C-72B4F4B168F7Q26748450-3FB0BC36-97D7-4C10-8333-3CEA79E7A517Q26752277-AFA4C367-158E-4F29-B068-7710CF4E0274Q26769977-C58F532A-12CB-444E-8116-A6EBFA97E947Q26772039-543429FC-C58C-492F-86F4-3FBF615B7930Q26774641-C878634C-BFE3-4003-A389-3F8EA217AE47Q27690636-A4C89608-5BA2-44B6-99DD-9CED4823DB9CQ30358614-3BD5C692-B887-455F-8AEF-D24EF5D766D2Q30393261-DB346353-05BE-4B44-959F-D271B9319AA7Q30395978-9270ED5F-AC39-466E-B087-D7001D2C14E4Q33551626-74037BC8-2B5B-4511-A838-9091B0DD0692Q36062083-EA90C2E0-8B35-4C81-9083-E291F282195FQ36086370-D012227F-6EE4-475F-9D38-0D11A83DD131Q36140389-E805B4E2-B380-4809-BA61-69F9EF0820E0Q36266545-13B2FF69-4491-4BEE-ABC4-735ED9B98602Q36378043-F918D65C-0E5A-4D8E-A6E0-39D0718124BBQ36549443-A744B1DC-3A91-430B-A8E8-6616B96B670FQ36664268-C7C6B118-A42F-447B-90E4-2F76D6DB3DBEQ36738884-934D4E1B-9638-401A-B638-F452CDB6EF3DQ36753953-1FA085B1-6BA5-414B-A0BC-E5894C5F7CABQ36821243-EF4B012A-8401-45B8-BFBA-FA88C8605B63Q36904198-0723664B-52E7-4DA0-95EF-323E628258BCQ37185612-F9BE8BC6-6780-4058-8CE3-D13CD00291E2Q37429172-F441BA85-06EB-4A69-A776-FF20320C4D94Q37709761-57D1AB53-2347-458A-AD72-78EBB461D370Q38470166-55ACFE47-DDE7-49A7-AF48-6BE3AFFE6CF9Q38575116-081D35D7-4EAA-47CD-BEDE-2ADD6717120CQ38679662-06828962-B130-45FE-AE8F-108F7A698C44Q38747135-32BCC32F-ECA7-47FB-B6A4-AC386651A481Q38764947-8021C44F-81D2-480C-BDE4-B1138DE10EFCQ38795324-1874EF1B-C4E7-4A26-99BB-ADDD7D42E580Q38817112-4F58BDCD-6B49-4778-A561-9A5FC1430D65Q38843995-5F6E8D59-427B-476F-AB18-F2C5BA8EF352Q38848885-533FAD6D-4EF9-4D62-94AD-8824E31ABC06Q38904089-8706B84F-FA3D-4EAD-953B-CF3FC05049FFQ38912327-7C0548A1-EE78-4991-81D3-C7C61A2881A1Q38920459-167172B7-A54E-4627-B158-994DD7270537Q38924569-978DFB92-E29F-44BF-B273-AECBF7C75DC7Q39041939-2850C8D1-0686-4177-A0F0-DB4F43362BEB
P2860
Oncolytic viruses and their application to cancer immunotherapy
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Oncolytic viruses and their application to cancer immunotherapy
@en
type
label
Oncolytic viruses and their application to cancer immunotherapy
@en
prefLabel
Oncolytic viruses and their application to cancer immunotherapy
@en
P2860
P1476
Oncolytic viruses and their application to cancer immunotherapy
@en
P2093
E Antonio Chiocca
P2860
P304
P356
10.1158/2326-6066.CIR-14-0015
P577
2014-04-01T00:00:00Z